Epitopea Strategic Cancer Collaboration with MSD(Merck)

“The Scius team provided timely and requisite media relations expertise in coordinating the announcement of our license and research collaboration with MSD, securing top tier media coverage of this impactful relationship. This has helped raise the visibility of our innovative CryptoMapTM platform for use in the discovery and development of RNA-immunotherapies for cancer patients.”

Alan C. Rigby

CEO of Epitopea

Objectives

Announce strategic cancer collaboration with major global pharma company
Position Epitopea as a pioneer in developing off-the-shelf immunotherapies, using its innovative CryptigenTM technology
Highlight the experience of the company’s world class leadership team, based in Montreal, Canada and Cambridge, UK

Strategy

Co-ordinated press release, pitch, and media Q&A
Drafted an engaging LI post
Pre-briefed select journalists under embargo and set up one-on-one media interviews.

Results

Extensive top tier international trade media coverage including BioWorld, Endpoints, Fierce Biotech, First Word Pharma, and The Pharma Letter
Local coverage in the two leading Cambridge business newspapers: Business Weekly and the Cambridge Independent